Abstracts tagged "genetics and systemic lupus erythematosus (SLE)"

Abstract Number: 1965 • 2019 ACR/ARP Annual Meeting
Determining a Polygenic Risk Score in Pediatric Systemic Lupus Erythematosus
Laura Lewandowski¹, Michael Ombrello ¹, Ivona Aksentijevich ², Zuoming Deng ³, Linda Hiraki ⁴, Earl D. Silverman ⁵, Chris Scott ⁶, Ana Barrera-Vargas ⁷, Sarfaraz Hasni ⁸ and Mariana Kaplan ⁹, ¹NIAMS, NIH, Bethesda, MD, ²NHGRI, NIH, Bethesda, MD, ³Biomining and Discovery Section/NIAMS/NIH, Bethesda, MD, ⁴Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Child Health Evaluative Sciences, Research Institute, The Hospital for Sick Children, Toronto, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada, ⁶University of Cape Town, Cape Town, South Africa, ⁷Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico, ⁸NIAMS, National Institutes of Health, Bethesda, MD, ⁹National Institute of Arthritis, Musculoskeletal, and Skin diseases/ National Institutes of Health, Bethesda
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a potentially life-threatening autoimmune disease with no cure. The onset of SLE is thought to be the result of…
Abstract Number: 2115 • 2018 ACR/ARHP Annual Meeting
Identification of Systemic Lupus Erythematosus Subgroups Using Electronic Health Record and Genetic Databases
Milena Gianfrancesco¹, Ishan Paranjpe², Julia Kay³, Joanne Nitiham⁴, Kimberly Taylor⁵, Cristina Lanata¹, Marina Sirota⁶, Lindsey A. Criswell⁷, Gabriela Schmajuk⁸ and Jinoos Yazdany², ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ⁴Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA, ⁵University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ⁶Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, ⁷University of California San Francisco, San Francisco, CA, ⁸San Francisco VA Medical Center, San Francisco, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multifactorial disease with genetic and environmental risk factors, and heterogeneous manifestations that encompass a wide range of disease…
Abstract Number: 66 • 2016 ACR/ARHP Annual Meeting
Very Rare X Chromosome Abnormalities in SLE and SjöGren’s May Localize X Gene Dose Effect
Rohan Sharma¹, Valerie M Harris², Joshua Cavett³, Biji T Kurien³, Ke Liu⁴, Kristi A. Koelsch⁵, Lida Radfar⁶, David M. Lewis⁷, Donald U. Stone⁸, C. Erick Kaufman⁹, Shibo Li¹⁰, Barbara M. Segal¹¹, Daniel J Wallace¹², Michael Weisman¹³, Jennifer A. Kelly¹⁴, Bernado Pons-Estel¹⁵, Roland Jonsson¹⁶, Jacques-Eric Gottenberg¹⁷, Juan-Manuel Anaya¹⁸, Deborah S. Cunninghame-Graham¹⁹, Vivian P. Bykerk²⁰, Gideon Hirschfield²¹, Gang Xie²², Wan-Fai Ng²³, Gunnel Nordmark²⁴, Per Eriksson²⁵, Roald Omdal²⁶, Nelson L. Rhodus²⁷, Maureen Rischmueller²⁸, Michael D. Rohrer²⁹, Marie Wahren-Herlenius³⁰, Torsten Witte³¹, Xavier Mariette³², Christopher J. Lessard³³, John B. Harley³⁴, Kathy L. Sivils³³, Astrid Rasmussen³⁵, R. Hal Scofield³³, Swamy Venturopalli³⁶, Xianglan Lu¹⁰, Pamela Hughes³⁷, Andrew J.W. Huang³⁸ and Corinnine Miceli-Richard³⁹, ¹Medical Service, US Department of Veterans Affaris Medical Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴3333 Burnet Ave., University of Cincinnati & Cincinnati Childre, Cincinnati, OH, ⁵U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, ⁶Oral Diagnosis and Radiology Department, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁷Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁸King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ⁹Medicine, University of Oklahoam Health Sciences Center, Oklahoma City, OK, ¹⁰Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Division of Rheumatology, University of Minnesota Medical School, Minneapolis, MN, ¹²Cedars-Sinai Medical Center, West Hollywood, CA, ¹³Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁴Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Sanatorio Parque, Rosario, Argentina, ¹⁶Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway, ¹⁷Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹⁸Center for Autoimmune Diseases Research (CREA). School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Bogotá, Colombia, ¹⁹Department of Medical and Molecular Genetics, King's College London, London, United Kingdom, ²⁰Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ²¹Centre for Liver Research, Institute of Biomedical Research, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ²²Mount Sinai Hospital, Toronto, ON, Canada, ²³Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ²⁴Rheumatology, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden, ²⁵University Hospital, Rheumatology clinic, Linköping, Sweden, ²⁶Department of internal medicine, Clinical Immunology unit, Stavanger, Norway, ²⁷Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ²⁸Rheumatology, Queen Elizabeth Hospital, Adelaide, Australia, ²⁹Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, ³⁰Department of Medicine, Experimental Rheumatology Unit, Solna, Sweden, ³¹Hannover Medical School, Hanover, Germany, ³²Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France, ³³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³⁴Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Childrens Hospital, Cincinnati, OH, ³⁵Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, USA, Oklahoma City, OK, ³⁶Rheumatology, Cedars Syani Medical Center, Los Angeles, CA, ³⁷Division of Oral and Maxillofacial Surgery, Department of Developmental and Surgical Science, University of Minnesota School of Dentistry, Minneapolis, MN, ³⁸Washington University,, St Louis, MO, ³⁹Rheumatology, Université Paris-Sud, Paris, France
Background/Purpose: Sjögren’s syndrome and systemic lupus erythematosus (SLE) are chronic, autoimmune diseases that are related by clinical and serological manifestations as well as genetic risks.…
Abstract Number: 3103 • 2016 ACR/ARHP Annual Meeting
Apolipoprotein L1 Risk Variants Associate with Prevalent Cardiovascular Disease in African American Systemic Lupus Erythematous Patients
Ashira Blazer¹, Robert M Clancy², H. Michael Belmont³, Peter M. Izmirly³, Androo Markham⁴ and Jill P. Buyon⁴, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY
Background/Purpose: Two Apolipoprotein L1 (APOL1) risk variants (RV), G1 and G2, located on chromosome 22q12.3, have been associated with excess renal risk in African Americans…
Abstract Number: 656 • 2014 ACR/ARHP Annual Meeting
Breach of B Cell Tolerance in New Zealand Black Chromosome 1 Congenic Mice
Kieran Manion^1,2, Nan-Hua Chang³, Yuriy Baglaenko^1,2 and Joan Wither^1,3, ¹Immunology, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Toronto Western Research Institute, University Health Network, Toronto, ON, Canada, ³Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Mapping studies in the lupus-prone New Zealand Black (NZB) mouse strain identified an interval from 170.8-181 Mb on chromosome 1 sufficient to induce B…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].